Holen Sie sich die Stockscreener-App
0.36
7.43%
-0.0289
Handel nachbörslich:
.37
0.01
+2.78%
Werewolf Therapeutics Inc Aktie (HOWL) Neueste Nachrichten
RA Capital adjusts Werewolf Therapeutics (HOWL) stake to 10.6% ownership - Stock Titan
Werewolf Therapeutics Stock (US4433141076): valuation back in focus after recent pipeline updates - AD HOC NEWS
Werewolf Therapeutics Stock (US4433141076): Quarterly earnings keep biotech micro-cap in focus - AD HOC NEWS
Ra Capital sells $253,568 in Werewolf Therapeutics (NASDAQ:HOWL) stock - Investing.com
RA Capital funds trim Werewolf Therapeutics (HOWL) stake with 678K-share sale - Stock Titan
Werewolf Therapeutics director Evnin sells $28,463 in company stock - Investing.com UK
Werewolf Therapeutics (HOWL) entities linked to Luke Evnin sell 76,928 shares - Stock Titan
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Werewolf Therapeutics director Luke Evnin sells $43,028 in shares - Investing.com UK
Werewolf Therapeutics director Luke Evnin sells $43,028 in shares By Investing.com - Investing.com India
Werewolf Therapeutics (NASDAQ: HOWL) director’s entities sell shares - Stock Titan
Werewolf Therapeutics director Luke Evnin sells $63,628 in stock - Investing.com
Werewolf Therapeutics director Luke Evnin sells $63,628 in stock By Investing.com - Investing.com Australia
Werewolf Therapeutics (NASDAQ: HOWL) director-affiliated funds sell 139,803 shares - Stock Titan
Werewolf Therapeutics Stock Stalls While HOWL Holds for Strategic Update - Bez Kabli
Werewolf Therapeutics (HOWL) Slips to $0.45 as Biotech Stock Holds Near Critical SupportDark Pool Volume - newsline.com
Werewolf Therapeutics Inc. Q1 2026 Earnings: Narrower Loss Surprises as Pipeline Progress ContinuesCEO Earnings Statement - The Legal Advocate
What's Behind the Recent Insider Selling at Werewolf Therapeutics (HOWL) - Kavout
Werewolf Therapeutics director Luke Evnin sells $66,200 in shares By Investing.com - Investing.com India
Werewolf Therapeutics director Luke Evnin sells $66,200 in shares - Investing.com
Director-linked funds trim Werewolf (NASDAQ: HOWL) stake via 141K-share sale - Stock Titan
[144] Werewolf Therapeutics, Inc. SEC Filing - Stock Titan
Werewolf Therapeutics (HOWL) Slides 7.6% as Shares Test Key Support at $0.43VOLD Alert - The Legal Advocate
MPM-linked funds tied to Werewolf (NASDAQ: HOWL) sell 191,762 shares under plan - Stock Titan
HOWL Q1 2026 Earnings: EPS Beats Estimates as Biotech Continues Pipeline ProgressBook Value Growth - The Legal Advocate
HOWL Q1 2026 Earnings: Narrowed Loss Exceeds Estimates, Stock RisesProfit Announcement - Newser
Werewolf Therapeutics (HOWL) Stages a Modest Rebound: Can the $0.44 Level Hold?Impulse Wave - The Legal Advocate
- The Legal Advocate
Werewolf Therapeutics director Luke Evnin sells $76,363 in stock By Investing.com - Investing.com India
Werewolf Therapeutics director Luke Evnin sells $76,363 in stock - Investing.com UK
Evnin-linked funds sell 171K Werewolf Therapeutics (HOWL) shares - Stock Titan
Werewolf Therapeutics Stock Rises Over 5% After Hours On Workforce Reduction, Including Executives - Stocktwits
Werewolf Therapeutics (HOWL) Stock: Down -3.84%, Support Test at $0.47 2026-05-18ATR Levels - newser.com
Werewolf Therapeutics (HOWL) price target increased by 12.00% to 7.14 - MSN
Werewolf Therapeutics (HOWL) price target increased by 20.19% to 6.38 - MSN
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):